 Hemorrhagic events therapy recombinant tissue-type plasminogen activator heparin aspirin acute myocardial infarction Results Thrombolysis Myocardial Infarction TIMI Phase II Trial OBJECTIVES effects invasive procedures hemostatic clinical variables timing beta-blocker therapy doses recombinant plasminogen activator rt-PA hemorrhagic events DESIGN multicenter trial SETTING Hospitals Thrombolysis Myocardial Infarction Phase II trial TIMI II INTERVENTIONS Patients rt-PA heparin total dose rt-PA mg first patients mg patients Patients invasive strategy coronary arteriography percutaneous angioplasty feasible hours start thrombolytic therapy conservative strategy coronary arteriography recurrent spontaneous exercise-induced ischemia Eligible patients immediate intravenous deferred beta-blocker therapy MEASUREMENTS Patients hemorrhagic events hospitalization MAIN RESULTS patients rt-PA regimen major minor hemorrhagic events common invasive conservative strategy Major minor hemorrhagic events extent fibrinogen breakdown peak rt-PA levels thrombocytopenia prolongation partial thromboplastin time APTT seconds weight kg female gender physical signs cardiac decompensation Immediate intravenous beta-blocker therapy important effect hemorrhagic events delayed beta-blocker therapy Intracranial hemorrhages frequent patients rt-PA dose rt-PA dose extent plasmin-mediated hemostatic defect patients dose CONCLUSIONS morbidity due hemorrhagic complications invasive management strategy patients acute myocardial infarction findings complex interaction several factors occurrence hemorrhagic events thrombolytic therapy